[Company Logo Image] Compound validation and profiling in vitro and in vivo
Improved clinical predictability of preclinical studies
Subcutaneous and orthotopic human xenografts
Genetically modified organ specific tumour models
Receptor tyrosine kinase-driven breast cancer model

         Preclinical Concept Validation

Angiogenesis in vivo Model


Syngeneic tumour models
Pharmacokinetic studies
  Toxicology (GLP)
  Histology (Frozen Sections and Paraffin Embedded Sections)


Home vivoPharm Search Employment Feedback

Preclinical Service vivoPharm Search Employment Feedback



Our Mission

vivoPharm is your specialised partner for preclinical studies and offers:

  • Industrial standard to validate and profile compounds.
  • A highly motivated team and qualified personnel
  • An advisory board with many years of industrial experience in in vitro and in vivo pharmacology.
  • Experience in the conception, experimental design and evaluation of preclinical drug efficacy.
  • Determining of active and best tolerated doses of compounds.
  • Standard subcutaneous models and orthotopic models for major indication areas in oncology.
  • Innovative, standardised and highly efficient working methods.
  • A customised database application for reliable, secure data storage and data processing.
  • Standardised reports and statistical analysis.
  • Transparent customer relationship.
  • High quality and reliable efficacy studies, intermediate and final annotated reports.

Company Profile

vivoPharm is located in Adelaide, South Australia and uses laboratory space and the animal facility of The University of Adelaide. The company has extended experience in cell biology, molecular biology, transgenic technologies and in vivo pharmacology. Despite offering preclinical service to customers, vivoPharm has a R & D program to improve the clinical predictability of existing in vivo tumour models. Additionally vivoPharm has a program to develop together with partners novel genetically modified sophisticated or transgenic tumour models to improve the profiling of target-specific anti-cancer drugs.

You are visitor No.  Hit Counter




Send mail to webmaster@vivopharm.com with questions or comments about this web site.
Last modified: 18-Dec-2003